Mar 13, 2024 7:00 am EDT NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals
Mar 11, 2024 7:00 am EDT Eyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18th
Mar 5, 2024 8:00 am EST Eyenovia Congratulates Formosa Pharmaceuticals on FDA Approval of Clobetasol Propionate Ophthalmic Suspension 0.05% for the Treatment of Post-operative Inflammation and Pain Following Ocular Surgery
Feb 13, 2024 7:00 am EST Eyenovia Announces FDA Approval of Redwood City as Commercial Manufacturing Facility
Jan 16, 2024 7:00 am EST Eyenovia Re-Acquires Development and Commercialization Rights to MicroPine in the U.S. and Canada
Nov 13, 2023 4:05 pm EST Eyenovia Reports Third Quarter 2023 Financial Results and Provides Business Update
Nov 2, 2023 7:00 am EDT Eyenovia Announces FDA Approval of Coastline International as Contract Manufacturer to Initiate Mydcombi Commercial Production
Oct 30, 2023 7:00 am EDT Eyenovia to Sponsor Course on Drug Delivery Innovation at IJCAHPO’s 51st Annual Continuing Education (ACE) Program
Oct 9, 2023 7:00 am EDT Eyenovia to Present Data on Preservative-Free Microbial Integrity of the Optejet®